Top
Summary
All studies
Mortality
Serious outcomes
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
 
Analgesics⏵
Antiandrogens⏵
Antihistamines⏵
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Monoclonals⏵
Mpro inhibitors⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors⏵
TMPRSS2 inh.⏵
Thermotherapy
Vitamins⏵
More⏵

Other
Feedback
Home
 
Top
..
All cytokine adsorption..
..
Feedback
Home
c19early.org COVID-19 treatment researchCytokine AdsorptionCytokine Adsorption (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta
Home Adoption Other Treatments
@CovidAnalysis

Outcomes in COVID-19 cytokine adsorption studies

Home
@CovidAnalysis
All
Studies
Feedback
All studies   Mortality   Serious outcomes   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies -72% 2 83 Improvement, Studies, Patients Relative Risk Mortality -72% 2 83 RCTs -72% 2 83 RCT mortality -72% 2 83 Late -72% 2 83 Cytokine Adsorption for COVID-19 c19early.org June 2025 Favorscytokine adsorption Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ CYCOV Supady (RCT) -250% 3.50 [1.44-8.48] death 14/17 4/17 ECMO patients Improvement, RR [CI] Treatment Control CytoResc Stockmann (RCT) 9% 0.91 [0.46-1.81] death 23 (n) 26 (n) Ventilated patients Tau​2​ = 0.75, I​2​ = 82.6%, p = 0.43 Late treatment -72% 1.72 [0.46-6.45] 14/40 4/43 72% higher risk All studies -72% 1.72 [0.46-6.45] 14/40 4/43 72% higher risk 2 cytokine adsorption COVID-19 studies c19early.org June 2025 Tau​2​ = 0.75, I​2​ = 82.6%, p = 0.43 Effect extraction pre-specified(most serious outcome) Favors cytokine adsorption Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ CYCOV Supady (RCT) -250% 3.50 [1.44-8.48] 14/17 4/17 ECMO patients Improvement, RR [CI] Treatment Control CytoResc Stockmann (RCT) 9% 0.91 [0.46-1.81] 23 (n) 26 (n) Ventilated patients Tau​2​ = 0.75, I​2​ = 82.6%, p = 0.43 Late treatment -72% 1.72 [0.46-6.45] 14/40 4/43 72% higher risk All studies -72% 1.72 [0.46-6.45] 14/40 4/43 72% higher risk 2 cytokine adsorption COVID-19 mortality results c19early.org June 2025 Tau​2​ = 0.75, I​2​ = 82.6%, p = 0.43 Favors cytokine adsorption Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ CYCOV Supady (RCT) -250% 3.50 [1.44-8.48] death 14/17 4/17 ECMO patients Improvement, RR [CI] Treatment Control CytoResc Stockmann (RCT) 9% 0.91 [0.46-1.81] death 23 (n) 26 (n) Ventilated patients Tau​2​ = 0.75, I​2​ = 82.6%, p = 0.43 Late treatment -72% 1.72 [0.46-6.45] 14/40 4/43 72% higher risk All studies -72% 1.72 [0.46-6.45] 14/40 4/43 72% higher risk 2 cytokine adsorption COVID-19 serious outcomes c19early.org June 2025 Tau​2​ = 0.75, I​2​ = 82.6%, p = 0.43 Effect extraction pre-specified(most serious outcome) Favors cytokine adsorption Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ CYCOV Supady (RCT) -250% 3.50 [1.44-8.48] death 14/17 4/17 ECMO patients Improvement, RR [CI] Treatment Control CytoResc Stockmann (RCT) 9% 0.91 [0.46-1.81] death 23 (n) 26 (n) Ventilated patients Tau​2​ = 0.75, I​2​ = 82.6%, p = 0.43 Late treatment -72% 1.72 [0.46-6.45] 14/40 4/43 72% higher risk All studies -72% 1.72 [0.46-6.45] 14/40 4/43 72% higher risk 2 cytokine adsorption COVID-19 Randomized Controlled Trials c19early.org June 2025 Tau​2​ = 0.75, I​2​ = 82.6%, p = 0.43 Effect extraction pre-specified(most serious outcome) Favors cytokine adsorption Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ CYCOV Supady (RCT) -250% 3.50 [1.44-8.48] 14/17 4/17 ECMO patients Improvement, RR [CI] Treatment Control CytoResc Stockmann (RCT) 9% 0.91 [0.46-1.81] 23 (n) 26 (n) Ventilated patients Tau​2​ = 0.75, I​2​ = 82.6%, p = 0.43 Late treatment -72% 1.72 [0.46-6.45] 14/40 4/43 72% higher risk All studies -72% 1.72 [0.46-6.45] 14/40 4/43 72% higher risk 2 cytokine adsorption COVID-19 RCT mortality results c19early.org June 2025 Tau​2​ = 0.75, I​2​ = 82.6%, p = 0.43 Favors cytokine adsorption Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ CYCOV Supady (RCT) -250% 3.50 [1.44-8.48] death 14/17 4/17 ECMO patients Improvement, RR [CI] Treatment Control CytoResc Stockmann (RCT) 9% 0.91 [0.46-1.81] death 23 (n) 26 (n) Ventilated patients Tau​2​ = 0.75, I​2​ = 82.6%, p = 0.43 Late treatment -72% 1.72 [0.46-6.45] 14/40 4/43 72% higher risk All studies -72% 1.72 [0.46-6.45] 14/40 4/43 72% higher risk 2 cytokine adsorption COVID-19 peer reviewed studies c19early.org June 2025 Tau​2​ = 0.75, I​2​ = 82.6%, p = 0.43 Effect extraction pre-specified(most serious outcome) Favors cytokine adsorption Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ CYCOV Supady (RCT) -250% 3.50 [1.44-8.48] death 14/17 4/17 ECMO patients Improvement, RR [CI] Treatment Control CytoResc Stockmann (RCT) 9% 0.91 [0.46-1.81] death 23 (n) 26 (n) Ventilated patients Cytokine adsorption COVID-19 outcomes c19early.org June 2025 Favors cytokine adsorption Favors control
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0